en English
af Afrikaanssq Shqipam አማርኛar العربيةhy Հայերենaz Azərbaycan dilieu Euskarabe Беларуская моваbn বাংলাbs Bosanskibg Българскиca Catalàceb Cebuanony Chichewazh-CN 简体中文zh-TW 繁體中文co Corsuhr Hrvatskics Čeština‎da Dansknl Nederlandsen Englisheo Esperantoet Eestitl Filipinofi Suomifr Françaisfy Fryskgl Galegoka ქართულიde Deutschel Ελληνικάgu ગુજરાતીht Kreyol ayisyenha Harshen Hausahaw Ōlelo Hawaiʻiiw עִבְרִיתhi हिन्दीhmn Hmonghu Magyaris Íslenskaig Igboid Bahasa Indonesiaga Gaeligeit Italianoja 日本語jw Basa Jawakn ಕನ್ನಡkk Қазақ тіліkm ភាសាខ្មែរko 한국어ku كوردی‎ky Кыргызчаlo ພາສາລາວla Latinlv Latviešu valodalt Lietuvių kalbalb Lëtzebuergeschmk Македонски јазикmg Malagasyms Bahasa Melayuml മലയാളംmt Maltesemi Te Reo Māorimr मराठीmn Монголmy ဗမာစာne नेपालीno Norsk bokmålps پښتوfa فارسیpl Polskipt Portuguêspa ਪੰਜਾਬੀro Românăru Русскийsm Samoangd Gàidhligsr Српски језикst Sesothosn Shonasd سنڌيsi සිංහලsk Slovenčinasl Slovenščinaso Afsoomaalies Españolsu Basa Sundasw Kiswahilisv Svenskatg Тоҷикӣta தமிழ்te తెలుగుth ไทยtr Türkçeuk Українськаur اردوuz O‘zbekchavi Tiếng Việtcy Cymraegxh isiXhosayi יידישyo Yorùbázu Zulu

New Research: Treating Prostate Cancer with Stereotactic Body Radiation Therapy

In the last decade, stereotactic body radiation therapy (SBRT) has become an increasingly accepted treatment approach for prostate cancer thanks to clinical studies and research completed by some of the world’s top cancer experts. Below are three recently published studies that support the use of SBRT for prostate cancer. The advanced approach delivers precisely focused radiation to a patient’s prostate cancer in five or fewer outpatient treatments. The pinpoint precision of radiation delivery minimizes damage to surrounding healthy tissue.

  • A study recently presented at the 2014 Genitourinary Cancers Symposium followed the treatment-related bother of 228 patients with localized prostate cancer for two years following CyberKnife SBRT. Bother is a term used to refer to various side effects a man may experience as a result of treatment. The study titled “œBother Following Stereotactic Body Radiation Therapy for Clinically Localized Prostate Cancer“ concluded that SBRT for clinically localized prostate cancer was well tolerated in relation to sexual, urinary and bowel bother.

These clinical studies are among the research that has prompted insurance providers and cancer organizations across the country to announce support and coverage of SBRT as an appropriate treatment option for prostate cancer. If you’™re interested in learning more about how our center treats prostate cancer with SBRT, click here.

This is not intended as medical advice to replace the expertise and judgment of your health care team. It is intended to help you and your family make informed decisions, together with your doctor.